Recursion Pharmaceuticals Inc Clas (RXRX) financials
Recursion Pharmaceuticals Inc Clas revenue and earnings by year
Recursion Pharmaceuticals Inc Clas's revenue was $74.7 million in the fiscal year to December 31, 2025, up 26.9% from the year before. Net income was -$645 million, -863.4% of revenue. Since the fiscal year to December 31, 2019, revenue has grown 78.3% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 75 | 59 | 45 | 40 | 10 | 4 | 2 |
| Revenue growth | 26.9% | 32.0% | 11.9% | 291.5% | 156.9% | 70.8% | — |
| Gross profit | 4 | 14 | 2 | -8 | — | — | — |
| Gross margin | 5.0% | 23.1% | 4.5% | -21.2% | — | — | — |
| Operating income | -648 | -479 | -350 | -246 | -183 | -85 | -62 |
| Operating margin | -867.9% | -814.1% | -785.3% | -616.7% | -1795.8% | -2135.7% | -2692.6% |
| Net income | -645 | -464 | -328 | -239 | -186 | -87 | -62 |
| Net margin | -863.4% | -788.0% | -736.0% | -601.0% | -1832.2% | -2196.0% | -2668.3% |
| Diluted EPS | -$1.44 | -$1.69 | -$1.58 | -$1.36 | -$1.49 | -$3.99 | — |
| Free cash flow | -378 | -373 | -300 | -121 | -198 | -51 | -61 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open RXRX in Markets.
How Recursion Pharmaceuticals Inc Clas makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| License & Service | $7.30M | 95.2% |
| Grant | $367K | 4.8% |
See also: RXRX returns
No forecast, no recommendation. This page describes Recursion Pharmaceuticals Inc Clas from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.